The Yin and Yang of adaptive immunity in allogeneic hematopoietic cell transplantation: Donor antigen-presenting cells can either augment or inhibit donor T cell alloreactivity

Advances in Experimental Medicine and Biology

Volumn 590, Issue , 2007, Pages 69-87

  Li, Jian Ming ^a   Waller, Edmund K ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; GAMMA INTERFERON; MARKER; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADAPTIVE IMMUNITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANTIGEN PRESENTING CELL; BONE MARROW DEPRESSION; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL SELECTION; CHINESE MEDICINE; CLONAL ANERGY; CONFERENCE PAPER; DENDRITIC CELL; DONOR; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; GRANULOCYTE; IMMUNE RESPONSE; IMMUNOREGULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 84934440059     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-34814-8_5     Document Type: Conference Paper

References (41)

1. W.D. Shlomchik, M.S. Couzens, C.B. Tang, J. McNiff, M.E. Robert, J. Liu, M.J. Shlomchik and S.G. Emerson. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285(5426):412-415 (1999).
2. C.C. Matte, J. Liu, J. Cormier, B.E. Anderson, I. Athanasiadis, D. Jain, J. McNiff and W.D. Shlomchik. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 10(9):987-992 (2004).
3. E.K. Waller, H. Rosenthal, T.W. Jones, J. Peel, S. Lonial, A. Langston, I. Redei, I. Jurickova and M.W. Boyer. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 97(10):2948-2956 (2001).
4. V. Reddy, J.A. Iturraspe, A.C. Tzolas, H.U. Meier-Kriesche, J. Schold and J.R. Wingard. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death and acute graft-versus-host disease. Blood 103(11):4330-4335 (2004).
5. B. Pulendran, J.L. Smith, G. Caspary, K. Brasel, D Pettit, E. Maraskovsky and C.R. Maliszewski. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 96(3):1036-1041 (1999).
6. R. Maldonado-Lopez, T. De Smedt, P. Michel, J. Godfroid, B. Pajak, C. Heirman, K. Thielemans, O. Leo, J. Urbain and M. Moser. CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 189(3):587-592 (1999).
7. M.C. Rissoan, V. Soumelis, N. Kadowaki, G. Grouard, F. Briere, R. de Waal Malefyt and Y.J. Liu. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283(5405):1183-1186 (1999).
8. F.P. Siegal, N. Kadowaki, M. Shodell, P.A. Fitzgerald-Bocarsly, K. Shah, S. Ho, S. Antonenko and Y.J. Liu. The nature of the principal type 1 interferon-producing cells in human blood. Science 284(5421):1835- 1837 (1999).
9. M. Cella, D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A. Lanzavecchia and M. Colonna. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5(8):919-923 (1999).
10. F. Sallusto and A. Lanzavecchia. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J Exp Med 189(4):611-614 (1999).
11. A. Lanzavecchia and F. Sallusto. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 13(3):291-298 (2001).
12. M.F. Lipscomb and B.J. Masten. Dendritic cells: immune regulators in health and disease. Physiol Rev 82(1):97-130 (2002).
13. M. O'Keeffe, H. Hochrein, D. Vremec, I. Caminschi, J.L. Miller, E.M. Anders, L. Wu, M.H. Lahoud, S. Henri, B. Scott, P. Hertzog, L. Tatarczuch and K. Shortman. Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. J Exp Med 196(10):1307-1319 (2002).
14. M. O'Keeffe, H. Hochrein, D. Vremec, B. Scott, P. Hertzog, L. Tatarczuch and K. Shortman. Dendritic cell precursor populations of mouse blood: identification of the murine homologues of human blood plasmacytoid pre-DC2 and CD11c+ DC1 precursors. Blood 101(4):1453-1459 (2003).
15. R. Pelayo, J. Hirose, J. Huang, K.P. Garrett, A. Delogu, M. Busslinger and P.W. Kincade. Derivation of 2 categories of plasmacytoid dendritic cells in murine bone marrow. Blood 105(11):4407-4415 (2005).
16. C. Ruedl and M.F. Bachmann. CTL priming by CD8(+) and CD8(-) dendritic cells in vivo. Eur J Immunol 29(11):3762-3767 (1999).
17. G. Schlecht, C. Leclerc and G. Dadaglio. Induction of CTL and nonpolarized Th cell responses by CD8alpha(+) and CD8alpha(-) dendritic cells. J Immunol 167(8):4215-4221 (2001).
18. A.D. Billiau, S. Fevery, O. Rutgeerts, W. Landuyt and M. Waer. Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. Blood 102(2):740-748 (2003).
19. J.M. Li and E.K. Waller. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 10(8):540-551 (2004).
20. S. Gillis and S.B. Mizel. T-cell lymphoma model for the analysis of interleukin 1-mediated T-cell activation. Proc Natl Acad Sci USA 78(2):1133-1137 (1981).
21. E.K. Waller, A.M. Ship, S. Mittelstaedt, T.W. Murray, R. Carter, I. Kakhniashvili, S. Lonial, J.T. Holden and M.W. Boyer. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. Blood 94(9):3222-3233 (1999).
22. C.R. Giver, R.O. Montes, S. Mittestaedt, J.M. Li, D.L. Jaye, S. Lonial, M.W. Boyer and E.K. Waller. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Biol Blood Marrow Transplant 9(10):616-632 (2003).
23. D.H. Fowler, K. Kurasawa, A. Husebekk, P.A. Cohen and R.E. Gress. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction: regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 152(3):1004-1013 (1994).
24. R.C. Budd, J.C. Cerottini, C. Horvath, C. Bron, T. Pedrazzini, R.C. Howe and H.R. MacDonald. Distinction of virgin and memory T lymphocytes: stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic stimulation. J Immunol 138(10):3120-3129 (1987).
25. T.L. Walunas, D.S. Bruce, L. Dustin, D.Y. Loh and J.A. Bluestone. Ly-6C is a marker of memory CD8+ T cells. J Immunol 155(4):1873-1883 (1995).
26. J.M. Curtsinger, D.C. Lins and M.F. Mescher. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. J Immunol 160(7):3236- 3243 (1998).
27. K.R. Cooke, L. Kobzik, T.R. Martin, J. Brewer, J. Delmonte Jr., J.M. Crawford and J.L. Ferrara. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: the roles of minor H antigens and endotoxin. Blood 88(8):3230-3239 (1996).
28. K.R. Cooke, W. Krenger, G. Hill, T.R. Martin, L. Kobzik, J. Brewer, R. Simmons, J.M. Crawford, M.R. van den Brink and J.L. Ferrara. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood 92(7):2571-2580 (1998).
29. J.M. Crawford. Graft-versus host disease of the liver. In Graft-versus-host disease, pp. 315-333. Ed. J.L. Ferrara, H.J. Deeg and S.J. Burakoff. New York: Marcel Dekker (1996).
30. A. Mowat. Intestinal graft-versus host disease. In Graft-versus-host disease, pp. 337-384. Ed. J.L. Ferrara, H.J. Deeg and S.J. Burakoff. New York: Marcel Dekker (1996).
31. D. Stull and S. Gillis. Constitutive production of interleukin 2 activity by a T cell hybridoma. J Immunol 126(5):1680-1683 (1981).
32. C. Kurts, H. Kosaka, F.R. Carbone, J.F. Miller and W.R. Heath. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 186(2):239-245 (1997).
33. K. Inaba, S. Turley, F. Yamaide, T. Iyoda, K. Mahnke, M. Inaba, M. Pack, M. Subklewe, B. Sauter, D. Sheff, M. Albert, N. Bhardwaj, I. Mellman and R.M. Steinman. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 188(11):2163-2173 (1998).
34. E.K. Waller, H. Rosenthal and L. Sagar. DC2 effect on survival following allogeneic bone marrow transplantation. Oncology (Huntington) 16(1 Suppl 1):19-26 (2002).
35. R.S. Negrin, C.R. Kusnierz-Glaz, B.J. Still, J.R. Schriber, N.J. Chao, G.D. Long, C. Hoyle, W.W. Hu, S.J. Horning, B.W. Brown, K.G. Blume and S. Strober. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 85(11):3334-3341 (1995).
36. C. Arber, A. BitMansour, T.E. Sparer, J.P. Higgins, E.S. Mocarski, I.L. Weissman, J.A. Shizuru and J.M. Brown. Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. Blood 102(2):421-428 (2003).
37. S.D. Nimer, J. Giorgi, J.L. Gajewski, N. Ku, G.J. Schiller, K. Lee, M. Territo, W. Ho, S. Feig, M. Selch, V. Isacescu, T.A. Reichert and R.E. Champlin. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomized controlled trial. Transplantation 57(1):82-87 (1994).
38. E.P. Alyea, R.J. Soiffer, C. Canning, D. Neuberg, R. Schlossman, C. Pickett, H. Collins, Y. Wang, K.C. Anderson and J. Ritz. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91(10):3671-3680 (1998).
39. S. Giralt, J. Hester, Y. Huh, C. Hirsch-Ginsberg, G. Rondon, D. Seong, M. Lee, J. Gajewski, K. Van Besien, I. Khouri, R. Mehra, D. Przepiorka, M. Korbling, M. Talpaz, H. Kantarjian, H. Fischer, A. Deisseroth and R. Champlin. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86(11):4337-4343 (1995).
40. K.R. Oettel, O.H. Wesly, M.R. Albertini, J.A. Hank, O. Iliopolis, J.A. Sosman, K. Voelkerding, S.Q. Wu, S.S. Clark and P.M. Sondel. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient. Blood 83(11):3390-3402 (1994).
41. G.R. Hill, J.M. Crawford, K.R. Cooke, Y.S. Brinson, L. Pan and J.L. Ferrara. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90(8):3204-3213 (1997).